$177.51 Million in Sales Expected for BioScrip Inc (BIOS) This Quarter

Wall Street analysts expect BioScrip Inc (NASDAQ:BIOS) to post sales of $177.51 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for BioScrip’s earnings, with estimates ranging from $177.01 million to $178.00 million. BioScrip reported sales of $168.58 million in the same quarter last year, which suggests a positive year over year growth rate of 5.3%. The business is expected to issue its next quarterly earnings results on Thursday, May 9th.

According to Zacks, analysts expect that BioScrip will report full year sales of $754.46 million for the current financial year, with estimates ranging from $750.72 million to $761.65 million. For the next year, analysts forecast that the business will post sales of $800.52 million, with estimates ranging from $794.00 million to $807.03 million. Zacks’ sales calculations are a mean average based on a survey of research firms that that provide coverage for BioScrip.

BioScrip (NASDAQ:BIOS) last released its earnings results on Friday, March 15th. The company reported ($0.14) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.03) by ($0.11). The firm had revenue of $183.57 million during the quarter, compared to the consensus estimate of $188.39 million. The company’s revenue was up .5% on a year-over-year basis. During the same period in the prior year, the business posted ($0.03) EPS.



BIOS has been the topic of several research analyst reports. BidaskClub upgraded BioScrip from a “hold” rating to a “buy” rating in a research note on Friday, January 11th. TheStreet upgraded BioScrip from a “d+” rating to a “c-” rating in a research note on Monday, November 26th. Zacks Investment Research downgraded BioScrip from a “hold” rating to a “sell” rating in a research note on Thursday, January 3rd. Stephens downgraded BioScrip from an “overweight” rating to an “equal weight” rating and set a $2.51 price objective on the stock. in a research note on Monday, March 18th. Finally, Canaccord Genuity dropped their price objective on BioScrip from $5.00 to $3.50 and set a “buy” rating on the stock in a research note on Monday, March 18th. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and three have issued a buy rating to the company. BioScrip currently has a consensus rating of “Hold” and an average price target of $4.70.

Shares of BioScrip stock traded up $0.09 on Friday, hitting $1.99. 74,295 shares of the company’s stock traded hands, compared to its average volume of 2,274,539. The stock has a market cap of $243.49 million, a P/E ratio of -4.06 and a beta of 0.76. BioScrip has a 52-week low of $1.86 and a 52-week high of $4.14.

A number of institutional investors have recently bought and sold shares of BIOS. Vanguard Group Inc. increased its holdings in shares of BioScrip by 0.5% in the third quarter. Vanguard Group Inc. now owns 5,987,679 shares of the company’s stock worth $18,562,000 after purchasing an additional 27,904 shares during the period. Tibra Equities Europe Ltd bought a new position in shares of BioScrip during the 4th quarter worth approximately $503,000. Caxton Associates LP bought a new position in shares of BioScrip during the 4th quarter worth approximately $52,000. Royce & Associates LP raised its stake in shares of BioScrip by 3.6% during the 3rd quarter. Royce & Associates LP now owns 2,204,000 shares of the company’s stock worth $6,832,000 after acquiring an additional 77,000 shares in the last quarter. Finally, BlackRock Inc. raised its stake in shares of BioScrip by 0.4% during the 3rd quarter. BlackRock Inc. now owns 7,616,244 shares of the company’s stock worth $23,610,000 after acquiring an additional 31,899 shares in the last quarter. Institutional investors and hedge funds own 82.51% of the company’s stock.

About BioScrip

BioScrip, Inc provides infusion solutions in the United States. It engages in the preparation, delivery, administration, and clinical monitoring of pharmaceutical treatments that are administered to a patient through intravenous, subcutaneous, intramuscular, intra-spinal, and enteral methods. The company is primarily involved in the intravenous administration of medications to treat a range of acute and chronic conditions, such as infections, nutritional deficiencies, immunologic and neurologic disorders, cancer, pain, and palliative care.

Featured Article: How Do Mutual Funds Work?

Get a free copy of the Zacks research report on BioScrip (BIOS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for BioScrip (NASDAQ:BIOS)

Receive News & Ratings for BioScrip Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip and related companies with MarketBeat.com's FREE daily email newsletter.